血管抑制剂
医学
贝伐单抗
视力
眼科
黄斑水肿
置信区间
随机对照试验
视网膜中央静脉阻塞
不利影响
视网膜分支静脉阻塞
闭塞
外科
内科学
化疗
作者
Maartje J.C. Vader,Ann-Sofie M.E. Schauwvlieghe,Frank D. Verbraak,Greetje Dijkman,Johanna M. M. Hooymans,Leonoor I. Los,Aeilko H. Zwinderman,Tünde Pető,Carel B. Hoyng,Remko van Leeuwen,Johannes R. Vingerling,Yvonne de Jong‐Hesse,Janneke J.C. van Lith-Verhoeven,Marcel G. W. Dijkgraaf,Reinier O. Schlingemann
标识
DOI：10.1016/j.oret.2019.12.019
摘要
This study showed, based on the change in visual acuity, that bevacizumab is noninferior to ranibizumab for patients with ME resulting from RVO of either subtype when receiving monthly injections for a period of 6 months. In addition, anatomic and safety outcomes did not differ between treatment groups. Based on our findings, bevacizumab may be an effective alternative to ranibizumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
热心市民小杨
lxaiczn
无极微光
大力的灵雁
互助
寻道图强
干净的琦
felyne
andrele
GingerF
cz
YifanWang
常川禹
pancake
penxyy
L_BD
橘x
xzn1123
萝卜
Arthur
皖公网安备34019202002308
